AU2006216420B2 - Compositions and methods for treating and preventing cardiomyopathy and heart disease - Google Patents

Compositions and methods for treating and preventing cardiomyopathy and heart disease Download PDF

Info

Publication number
AU2006216420B2
AU2006216420B2 AU2006216420A AU2006216420A AU2006216420B2 AU 2006216420 B2 AU2006216420 B2 AU 2006216420B2 AU 2006216420 A AU2006216420 A AU 2006216420A AU 2006216420 A AU2006216420 A AU 2006216420A AU 2006216420 B2 AU2006216420 B2 AU 2006216420B2
Authority
AU
Australia
Prior art keywords
poloxamer
subject
present
composition
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006216420A
Other languages
English (en)
Other versions
AU2006216420A1 (en
Inventor
Joseph Metzger
Dan Michele
Dewayne Townsend
Soichiro Yasuda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan (System)
Original Assignee
University of Michigan (System)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan (System) filed Critical University of Michigan (System)
Publication of AU2006216420A1 publication Critical patent/AU2006216420A1/en
Application granted granted Critical
Publication of AU2006216420B2 publication Critical patent/AU2006216420B2/en
Priority to AU2010214636A priority Critical patent/AU2010214636A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006216420A 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease Ceased AU2006216420B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010214636A AU2010214636A1 (en) 2005-02-25 2010-08-24 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65657005P 2005-02-25 2005-02-25
US60/656,570 2005-02-25
PCT/US2006/006862 WO2006091941A2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010214636A Division AU2010214636A1 (en) 2005-02-25 2010-08-24 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Publications (2)

Publication Number Publication Date
AU2006216420A1 AU2006216420A1 (en) 2006-08-31
AU2006216420B2 true AU2006216420B2 (en) 2010-07-15

Family

ID=36928113

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2006216420A Ceased AU2006216420B2 (en) 2005-02-25 2006-02-27 Compositions and methods for treating and preventing cardiomyopathy and heart disease
AU2010214636A Abandoned AU2010214636A1 (en) 2005-02-25 2010-08-24 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2010214636A Abandoned AU2010214636A1 (en) 2005-02-25 2010-08-24 Compositions and methods for treating and preventing cardiomyopathy and heart disease

Country Status (8)

Country Link
US (2) US7846426B2 (enExample)
EP (1) EP1853280B1 (enExample)
JP (1) JP5042041B2 (enExample)
AT (1) ATE546147T1 (enExample)
AU (2) AU2006216420B2 (enExample)
CA (1) CA2599219C (enExample)
ES (1) ES2380047T3 (enExample)
WO (1) WO2006091941A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101534843A (zh) * 2006-08-01 2009-09-16 普里克萨斯医药股份有限公司 泊洛沙姆用于预防和/或治疗心力衰竭的用途
WO2008124088A2 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009070793A1 (en) * 2007-11-29 2009-06-04 Pluromed, Inc. Endoscopic mucosal resectioning using purified inverse thermosensitive polymers
EP2234625B8 (en) * 2007-12-17 2013-10-30 The Regents of the University of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
US9867547B2 (en) 2012-11-29 2018-01-16 Siemens Healthcare Gmbh System and method to calculate cardiac characteristics
US20160067246A1 (en) * 2013-04-19 2016-03-10 Cedars-Sinai Medical Center Use of phosphodiesterase 5a inhibitors for the treatment of muscular dystrophy
JP2016533377A (ja) * 2013-10-16 2016-10-27 マスト セラピューティクス インコーポレイテッドＭａｓｔ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 利尿薬によって誘発される血漿量の変化
AU2015287993B2 (en) 2014-07-07 2020-10-29 Liferaft Biosciences, Inc. A poloxamer composition free of long circulating material and methods for production and uses thereof
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
WO2016007542A1 (en) 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
EP3965734A4 (en) * 2019-05-06 2022-12-14 Arshintseva, Elena Valentinovna Method for increasing cancer patient's haemoglobin level

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342247B1 (en) * 1995-06-07 2002-01-29 Sanofi-Synthelabo Pharmaceutical compositions containing irbesartan

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0576612B1 (en) * 1991-03-19 1999-12-01 Cytrx Corporation Polyoxypropylene/polyoxyethylene copolymers with improved biological activity
WO1992022202A1 (en) 1991-06-03 1992-12-23 Alpha Therapeutics Corporation Thrombolytic and perfluorochemical treatment for myocardial infraction
US6761824B2 (en) * 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
EP1335707A4 (en) * 2000-10-24 2005-07-06 Smithkline Beecham Corp NEW CARVEDILOL FORMULATIONS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342247B1 (en) * 1995-06-07 2002-01-29 Sanofi-Synthelabo Pharmaceutical compositions containing irbesartan

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHAER, G et al. Circulation. 1996; vol.94: 298-307 *
YASUDA, S et al. Circulation. 2004; vol.110(7): S *

Also Published As

Publication number Publication date
WO2006091941A2 (en) 2006-08-31
EP1853280A2 (en) 2007-11-14
JP5042041B2 (ja) 2012-10-03
CA2599219C (en) 2011-09-20
AU2010214636A1 (en) 2010-09-16
ES2380047T3 (es) 2012-05-08
US7846426B2 (en) 2010-12-07
US20110044935A1 (en) 2011-02-24
CA2599219A1 (en) 2006-08-31
US8580245B2 (en) 2013-11-12
WO2006091941A3 (en) 2007-01-04
AU2006216420A1 (en) 2006-08-31
JP2008531598A (ja) 2008-08-14
ATE546147T1 (de) 2012-03-15
EP1853280B1 (en) 2012-02-22
US20080260681A1 (en) 2008-10-23
EP1853280A4 (en) 2008-10-29

Similar Documents

Publication Publication Date Title
US8580245B2 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
RU2503453C2 (ru) Фармацевтические композиции, обладающие желаемой биодоступностью
AU2016273858B2 (en) Aqueous pharmaceutical formulation of tapentadol for oral administration
US20220273660A1 (en) Mek inhibitor for treatment of stroke
JP5425631B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
JP5560201B2 (ja) 骨格筋欠損症を治療および予防するための組成物および方法
US9694003B2 (en) Formulations and methods for treating high intraocular pressure
KR20180127493A (ko) 승모판 질환으로 인한 무증상 심부전이 있는 환자에서 심장 크기의 감소 및/또는 임상적 증상 개시의 지연을 위한 피모벤단의 용도
CN101500557A (zh) 用于治疗癌症和血管发生的硝基呋喃化合物
FR3095755A1 (fr) Nouveaux médicaments cytoprotecteurs
US11123317B2 (en) Compositions for the treatment of autodigestion
US9155758B2 (en) Treatment of chronic progressive heart failure
BR112019012299A2 (pt) formulações farmacêuticas para o tratamento de glaucoma e métodos para a fabricação e uso das mesmas
JPWO2007132825A1 (ja) 医薬
JP2019515942A (ja) 急性腎不全の治療における使用のためのアンブリセンタン
US20180353446A1 (en) Compositions and methods of treating and/or preventing cancer
JP2004002370A (ja) 重症セプシス予防治療剤
JP4966019B2 (ja) 慢性移植片対宿主症におけるドライアイの予防および治療剤
JP4733348B2 (ja) 心不全、他の加齢関連臓器機能不全および加齢関連障害の予防のための、ならびに寿命を延長するための、ナトリウム−水素交換阻害剤であるカリポライドとａｃｅ阻害剤との組み合わせ製剤
WO2011066201A2 (en) Methods and systems for treating and preventing cardiac injury in dystrophic subjects
WO2016044902A1 (en) Pharmaceutical composition of 15-deoxy-delta-12,14-prostaglandin j2 in a poloxamer-based micellar system and its use for treatment of inflammatory conditions
RU2021130472A (ru) Твердые фармацевтические композиции для лечения hcv

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired